Drugs / THR-4109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00485017 | Aug 2007 → Jun 2008 | obesity disorder | Theracos | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THR-4109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00485017 ↗ |
| Route | Oral | “THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks” NCT00485017 ↗ |